Cargando…

Tumor Treating Fields Suppression of Ciliogenesis Enhances Temozolomide Toxicity

Tumor Treating Fields (TTFields) are low-intensity, alternating intermediate-frequency (200 kHz) electrical fields that extend survival of glioblastoma patients receiving maintenance temozolomide (TMZ) chemotherapy. How TTFields exert efficacy on cancer over normal cells or interact with TMZ is uncl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Ping, Tian, Jia, Ulm, Brittany S., Mallinger, Julianne C., Khoshbouei, Habibeh, Deleyrolle, Loic P., Sarkisian, Matthew R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962950/ https://www.ncbi.nlm.nih.gov/pubmed/35359402 http://dx.doi.org/10.3389/fonc.2022.837589

Ejemplares similares

PCM1 Depletion Inhibits Glioblastoma Cell Ciliogenesis and Increases Cell Death and Sensitivity to Temozolomide()
por: Hoang-Minh, Lan B., et al.
Publicado: (2016)

Cilia at the Crossroads of Tumor Treating Fields and Chemotherapy
por: Deleyrolle, Loic P., et al.
Publicado: (2023)

HDAC6 Signaling at Primary Cilia Promotes Proliferation and Restricts Differentiation of Glioma Cells
por: Shi, Ping, et al.
Publicado: (2021)

Increasing Ciliary ARL13B Expression Drives Active and Inhibitor-Resistant Smoothened and GLI into Glioma Primary Cilia
por: Shi, Ping, et al.
Publicado: (2023)

Heterogeneity of glioblastoma stem cells in the context of the immune microenvironment and geospatial organization
por: Silver, Aryeh, et al.
Publicado: (2022)

Molecular Evolution of a Glioblastoma Controlled With Tumor Treating Fields and Concomitant Temozolomide
por: Robins, H. Ian, et al.
Publicado: (2018)

Disruption of KIF3A in patient-derived glioblastoma cells: effects on ciliogenesis, hedgehog sensitivity, and tumorigenesis
por: Hoang-Minh, Lan B., et al.
Publicado: (2016)

Scalp-Sparing Radiation With Concurrent Temozolomide and Tumor Treating Fields (SPARE) for Patients With Newly Diagnosed Glioblastoma
por: Miller, Ryan, et al.
Publicado: (2022)

Case Report of Complete Radiological Response of a Thalamic Glioblastoma After Treatment With Proton Therapy Followed by Temozolomide and Tumor-Treating Fields
por: Stein, Marco, et al.
Publicado: (2020)

Mechanisms of ciliogenesis suppression in dividing cells
por: Goto, Hidemasa, et al.
Publicado: (2016)

Metabolomics Monitoring of Treatment Response to Brain Tumor Immunotherapy
por: Dastmalchi, Farhad, et al.
Publicado: (2021)

Temozolomide – Just a Radiosensitizer?
por: Kaina, Bernd, et al.
Publicado: (2022)

Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
por: Zhu, Jia, et al.
Publicado: (2022)

An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?
por: Teraiya, Milan, et al.
Publicado: (2023)

Dynamic control of the dopamine transporter in neurotransmission and homeostasis
por: Bu, Mengfei, et al.
Publicado: (2021)

The strategy for enhancing temozolomide against malignant glioma
por: Nakada, Mitsutoshi, et al.
Publicado: (2012)

Organized Pneumonia Secondary to Increasing Doses of Temozolomide
por: Marcos, Pedro J, et al.
Publicado: (2015)

Autophagy and Ciliogenesis
por: Yamamoto, Yasuhiro, et al.
Publicado: (2021)

Integrins and p53 pathways in glioblastoma resistance to temozolomide
por: Martin, Sophie, et al.
Publicado: (2012)

A Potential Mechanism of Temozolomide Resistance in Glioma–Ferroptosis
por: Hu, Zhifang, et al.
Publicado: (2020)

Methamphetamine Reduces LTP and Increases Baseline Synaptic Transmission in the CA1 Region of Mouse Hippocampus
por: Swant, Jarod, et al.
Publicado: (2010)

Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities
por: Daniel, Paul, et al.
Publicado: (2019)

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma
por: Ge, Jingjing, et al.
Publicado: (2021)

Methamphetamine neurotoxicity, microglia, and neuroinflammation
por: Shaerzadeh, Fatemeh, et al.
Publicado: (2018)

Dose-volume analysis for respiratory toxicity in intrathoracic esophageal cancer patients treated with definitive chemoradiotherapy using extended fields
por: Tanabe, Satoshi, et al.
Publicado: (2013)

LAPTM5–CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance
por: Berberich, Anne, et al.
Publicado: (2020)

Identifying Predictive Gene Expression and Signature Related to Temozolomide Sensitivity of Glioblastomas
por: Cai, Hong-Qing, et al.
Publicado: (2020)

ITGA5 Predicts Dual-Drug Resistance to Temozolomide and Bevacizumab in Glioma
por: Shi, Ying, et al.
Publicado: (2021)

Identification and verification of the temozolomide resistance feature gene DACH1 in gliomas
por: Gu, Qiang, et al.
Publicado: (2023)

Fibroblast Growth Factor Receptor 3 Amplified Metastatic Melanoma Treated With Erdafitinib
por: Sarkisian, Saro, et al.
Publicado: (2020)

A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma
por: Fine, Howard, et al.
Publicado: (2023)

CUL4B Promotes Temozolomide Resistance in Gliomas by Epigenetically Repressing CDNK1A Transcription
por: Ye, Xiang, et al.
Publicado: (2021)

A bibliometric and visualization-based analysis of temozolomide research hotspots and frontier evolution
por: Song, Peng, et al.
Publicado: (2022)

EGF receptor kinase suppresses ciliogenesis through activation of USP8 deubiquitinase
por: Kasahara, Kousuke, et al.
Publicado: (2018)

Host Antiviral Response Suppresses Ciliogenesis and Motile Ciliary Functions in the Nasal Epithelium
por: Chen, Qianmin, et al.
Publicado: (2020)

4053 A TL1 Team Approach to CNS-Localized Delivery of Glial Cell-Derived Neurotrophic Factor for Treatment of Parkinson’s Disease
por: Farhadi, Shaheen, et al.
Publicado: (2020)

Combining stereotactic radiosurgery and systemic therapy for brain metastases: a potential role for temozolomide
por: Hardee, Matthew E., et al.
Publicado: (2012)

Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma
por: Yoshimoto, Koji, et al.
Publicado: (2012)

Hypoxia-Inducible Factor-1α Activity as a Switch for Glioblastoma Responsiveness to Temozolomide
por: Lo Dico, Alessia, et al.
Publicado: (2018)

Accelerated Hypofractionated Radiotherapy in the Era of Concurrent Temozolomide Chemotherapy in Elderly Patients with Glioblastoma Multiforme
por: Greer, Liana, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_84kmcd3b5u1k1s006pcu2c3a6q